Immunotherapeutic Effects of CTLA4Ig Fusion Protein on Murine EAE and GVHD.
- Author:
Seong Ok JANG
1
;
Soo Jong HONG
;
Hoon Sik CHO
;
Yong Hoon CHUNG
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: CTLA4Ig; T cell; anergy; costimulation; MLR; EAE; GVHD; CTL
- MeSH: Animals; Antibodies, Monoclonal; B7 Antigens; Blotting, Western; Cell Line; Electrophoresis, Polyacrylamide Gel; Encephalomyelitis, Autoimmune, Experimental; Graft Rejection; Graft vs Host Disease; Homicide; Humans; Immunosuppression; Lymphocyte Culture Test, Mixed; Lymphocytes; Mice; Silver Staining; Staphylococcal Protein A; T-Lymphocytes
- From:Immune Network 2003;3(4):302-309
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: CTLA4 (CD152), which is expressed on the surface of T cells following activation, has a much higher affinity for B7 molecules comparing to CD28, and is a negative regulator of T cell activation. In contrast to stimulating and agonistic capabilities of monoclonal antibodies specific to CTLA-4, CTLA4Ig fusion protein appears to act as CD28 antagonist and inhibits in vitro and in vivo T cell priming in variety of immunological conditions. We've set out to confirm whether inhibition of the CD28-B7 costimulatory response using a soluble form of human CTLA4Ig fusion protein would lead to persistent inhibition of alloreactive T cell activation. METHODS: We have used CHO-dhfr cell-line to produce CTLA4Ig fusion protein. After serum free culture of transfected cell line we purified this recombinant molecule by using protein A column. To confirm characterization of fusion protein, we carried out a series of Western blot, SDS-PAGE and silver staining analyses. We have also investigated the efficacy of CTLA4Ig in vitro such as mixed lymphocyte reaction (MLR) & cytotoxic T lymphocyte (CTL) response and in vivo such as experimental autoimmune encephalomyelitis (EAE), graft versus host disease (GVHD) and skin-graft whether this fusion protein could inhibit alloreactive T cell activation and lead to immunosuppression of activated T cell. RESULTS: In vitro assay, CTLA4Ig fusion protein inhibited immune response in T cell-specific manner: 1) Human CTLA4Ig inhibited allogeneic stimulation in murine MLR; 2) CTLA4Ig prevented the specific killing activity of CTL. In vivo assay, human CTLA4Ig revealed the capacities to induce alloantigen-specific hyporesponsiveness in mouse model: 1) GVHD was efficiently blocked by dose-dependent manner; 2) Clinical score of EAE was significantly decreased compared to nomal control; 3) The time of skin-graft rejection was not different between CTLA4Ig treated and control group. CONCLUSION: Human CTLA4Ig suppress the T cell-mediated immune response and efficiently inhibit the EAE, GVHD in mouse model. The mechanism of T cell suppression by human CTLA4Ig fusion protein may be originated from the suppression of activity of cytotoxic T cell. Human CTLA4Ig could not suppress the rejection in mouse skin-graft, this finding suggests that other mechanism except the suppression of cytotoxic T cell may exist on the suppression of graft rejection.
